Rigel Pharmaceuticals : Earnings Presentation FY 2024
RIGL
Q4 & FY 2024 Financial Results Presentation
March 4, 2025
1
Rigel Participants
Raul Rodriguez
Ray Furey, J.D.
Dave Santos
President &
Executive Vice President,
Executive Vice President &
Chief Executive Officer
General Counsel & Corporate Secretary
Chief Commercial Officer
Lisa Rojkjaer, M.D.
Dean Schorno
Executive Vice President &
Executive Vice President &
Chief Medical Officer
Chief Financial Officer
3
Growing Our Hematology and Oncology Business
Commercial Execution
ITP
mIDH1 R/R AML
RET fusion-positive
NSCLC and TC
Development & Expansion
Development Programs1
In-Licensing and Product Acquisition
Financial Discipline
ITP, immune thrombocytopenia; IDH1, isocitrate dehydrogenase-1; mIDH1, mutated IDH1; R/R, relapsed or refractory; AML, acute myeloid leukemia; RET, rearranged during transfection; NSCLC, non-small cell lung cancer; TC, thyroid cancer; MDS, myelodysplastic syndrome; IRAK1/4, interleukin receptor-associated kinases 1 and 4. 1. Investigational compounds in these indications and not approved by the
FDA. Please see Important Safety Information on slides 35-39. Please visit www.TAVALISSE.com for Full Prescribing Information. Please visit www.REZLIDHIA.com for Full Prescribing Information, including Boxed
4 WARNING. Please visit www.GAVRETO.com for Full Prescribing Information.
Continued Net Product Sales Growth
200
180
160
140
120
100
80
60
40
20
0
Annual Net Portfolio Sales ($M)
144.9
17.1
104.3
23.0
76.7
10.6
63.0
93.7
104.8
75.8
63.0
2021
2022
2023
2024
TAVALISSE
REZLIDHIA
GAVRETO
5 CAGR, compound annual growth rate.
Continued Net Product Sales Growth
Anticipate approximately 28% to 32% year-over-year growth in 2025 at the midpoint of guidance
200
180
160
140
120
100
80
60
40
20
0
Annual Net Portfolio Sales ($M)
185.0 - 192.0
144.9
17.1
104.3
23.0
76.7
10.6
63.0
93.7
104.8
75.8
63.0
2021
2022
2023
2024
2025 Outlook
TAVALISSE
REZLIDHIA
GAVRETO
6 CAGR, compound annual growth rate.
Commercial Portfolio
7
Please see Indications and Important Safety Information on slides 35-39. Please visit www.TAVALISSE.com for Full Prescribing Information. Please visit www.REZLIDHIA.com for Full Prescribing Information,
8 including Boxed WARNING. Please visit www.GAVRETO.com for Full Prescribing Information.
US Net Product Sales Growth
Q4 2024 Net Portfolio Sales grew $17.0M (58%) vs. Q4 2023
Annual Net Portfolio Sales ($M)
160
140
120
100
80
60
40
20
0
144.9
46.5
104.3
+58%
29.5
76.7
38.9
63.1
22.8
27.1
17.6
19.2
33.5
16.0
23.9
18.5
17.1
23.8
26.0
16.2
12.4
2021
2022
2023
2024
Q1
Q2
Q3
Q4
9
Q4 2024 Commercial Performance
Net Product Sales ($M)
$31.0M
Q4 2024 Net
TAVALISSE
REZLIDHIA
GAVRETO
Product Sales
46.5
21% Growth vs. Q4 2023
8.1
$7.4M
Q4 2024 Net
7.4
29.5
Product Sales
Axis Title
3.9
92% Growth vs. Q4 2023
31.0
$8.1M
Q4 2024 Net
25.7
Product Sales
Available June 2024
Q423
Q424
10 GAVRETO became commercially available from Rigel in June 2024.
Disclaimer
Rigel Pharmaceuticals Inc. published this content on March 04, 2025, and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 04, 2025 at 21:31:55.693.